Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.

ABSTRACT:

SUBMITTER: Chakraborty R 

PROVIDER: S-EPMC11319778 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature